DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 769-779

  Jonkers, Y M H ^a   Claessen, S M H ^a   Perren, A ^b   Schmitt, A M ^c   Hofland, L J ^d   De Herder, W ^d   De Krijger, R R ^d   Verhofstad, A A J ^e   Hermus, A R ^e   Kummer, J A ^f   Skogseid, B ^g   Volante, M ^h   Voogd, A C ^a   Ramaekers, F C S ^a   Speel, E J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Stadtspital Triemli   (Switzerland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOMAL INSTABILITY; CHROMOSOME 12Q; CHROMOSOME 3Q; CHROMOSOME 6Q; CHROMOSOME 7Q; FEMALE; FOLLOW UP; HUMAN; INSULINOMA; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ISLET CELL TUMOR; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL; TUMOR GROWTH; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTRINOMA; GENE DOSAGE; HUMANS; INSULINOMA; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 35948988564     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0111     Document Type: Article

References (38)

1. Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P & Hamilton TC 2003 LOT1(PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. Journal of Biological Chemistry 278 6041-6049.
2. Albarello L, Capitanio V, Zerbi A, Di Carlo V & Doglioni C 2004 Cytokeratin 19 expression in pancreatic endocrine tumors. Journal of the Pancreas 6 514.
3. Ali A, Serra S, Asa SL & Chetty R 2006 The predictive value of CK19 and CD99 in pancreatic endocrine tumors. American Journal of Surgical Pathology 30 1588-1594.
4. Barghorn A, Komminoth P, Bachmann D, Rùtimann K, Saremaslani P, Mulatta-Feurer S, Perren A, Roth J, Heitz PU & Speel EJM 2001a Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumors and is associated with metastatic progression. Journal of Pathology 94 451-458.
5. Barghorn A, Speel EJM, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU & Komminoth P 2001b Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. American Journal of Pathology 158 1903-1911.
6. Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G & Bordi C 2001 P27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Human Pathology 32 1094-1101.
7. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold AA 1997 Novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. Journal of Clinical Investigation 100 404-410.
8. Chung DC, Brown SB, Graeme-Cook F, Tillotson LG, Warshaw AL, Jensen RT & Arnold A 1998 Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Research 58 3706-3711.
9. Danforth DN, Gorden P & Brennan MF 1984 Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96 1027-1037.
10. Davies JJ, Wilson IM & Lam WL 2005 Array CGH technologies and their applications to cancer genomes. Chromosome Research 13 237-248.
11. Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL & Lauwers GY 2004 Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. American Journal of Surgical Pathology 28 1145-1153.
12. Goto A, Niki T, Terado Y, Fukushima J & Fukayama M 2004 Prevalence of CD99 protein expression in pancreatic endocrine tumors (PETs). Histopathology 45 384-392.
13. Graeme-Cook F, Bell DA, Flotte TJ, Preffer F, Pastel-Levy C, Nardi G & Compton C 1990 Aneuploidy in pancreatic insulinomas does not predict malignancy. Cancer 66 2365-2368.
14. Guo SS, Wu X, Shimoide AT, Wong J & Sawicki MP 2001 Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors. Journal of Surgical Research 96 284-288.
15. Guo SS, Arora C, Shimoide AT & Sawicki MP 2002 Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumors. Molecular and Cellular Endocrinology 190 109-114.
16. Heitz PU, von Herbay G, Klöppel G, Komminoth P, Kasper M, Höfler H, Muller KM & Oberholzer M 1987 The expression of subunits of human chorionic gonadotropin (hCG) by nontrophoblastic, nonendocrine, and endocrine tumors. American Journal of Clinical Pathology 88 467-472.
17. Heitz PU, Komminoth P, Perren A, Klimstra DS & Dayal Y 2004 Tumours of the endocrine pancreas. In Pathology, Genetics. Tumours of Endocrine Organs, pp 177-208. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press.
18. Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, Eriksson B, Akerström G, Westin G & Skogseid B 1999 Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN1-associated pancreatic endocrine tumors. Genes, Chromosomes and Cancer 26 258-264.
19. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD & Hua X 2003 Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Research 63 4204-4210.
20. Jonkers YMH, Claessen SMH, Perren A, Schmid S, Komminoth P, Verhofstad AA, Hofland LJ, de Krijger RR, Slootweg PJ, Ramaekers FCS et al. 2005 Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocrine-Related Cancer 12 435-447.
21. Jonkers YMH, Claessen SMH, Veltman JA, Geurts van Kessel A, Dinjens WNM, Skogseid B, Ramaekers FCS & Speel EJM 2006a Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenetic and Genome Research 115 289-297.
22. Jonkers YMH, Claessen SMH, Feuth T, Geurts van Kessel A, Ramaekers FCS, Veltman JA & Speel EJM 2006b Novel candidate tumor suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumorigenesis. Journal of Pathology 210 450-458.
23. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F & Pinkel D 1992 Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 818-821.
24. La Rosa S, Bianchi V, Rigoli E, Uccella S & Capella C 2005 The prognostic significance of cytokeratin 19 expression in pancreatic endocrine tumors (PETs). Virchows Archive 447 188.
25. Lee CS 1996 Lack of p53 immunoreactivity in pancreatic endocrine tumors. Pathology 28 139-141.
26. Ohike N & Morohoshi T 2001 Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathology International 51 770-777.
27. Ohike N & Morohoshi T 2005 Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis. Endocrine Pathology 16 33-40.
28. Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK & Spengler D 2000 The expression of the antiproliferative gene ZAC is lost or highly reduced in non-functioning pituitary adenomas. Cancer Research 60 6794-6799.
29. Pavelic K, Hrascan R, Kapitanovic S, Karapandza N, Vranes Z, Belicza M, Kruslin B & Cabrijan T 1995 Multiple genetic alterations in malignant metastatic insulinomas. Journal of Pathology 177 395-400.
30. Pinkel D & Albertson DG 2005 Array comparative genomic hybridization and its applications in cancer. Nature Genetics 37 11-17.
31. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL & Hansel DE 2003 Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. American Journal of Clinical Pathology 120 685-690.
32. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G et al. 2001 High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Research 61 285-292.
33. Schindl M, Kaczirek K, Kaserer K & Niederle B 2000 Is the new classification of neuroendocrine pancreatic tumors of clinical help? World Journal of Surgery 24 1312-1318.
34. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst N, Moch H et al 2007 WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. American Journal of Surgical Pathology [in press]
35. Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz PU et al. 1999 Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. American Journal of Pathology 155 1787-1794.
36. Speel EJM, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU & Komminoth P 2001 Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9q34 is an early event in insulinomas. Cancer Research 61 5186-5192.
37. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R & Corinaldesi R 2005 Endocrine pancreatic tumors: factors correlated with survival. Annals of Oncology 16 1806-1810.
38. Zhao J, Moch H, Scheidweiler AF, Baer A, Schäffer AA, Speel EJM, Roth J, Heitz PU & Komminoth P 2001 Genomic imbalances in the progression of endocrine pancreatic tumors. Genes, Chromosomes and Cancer 32 364-372.